Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine

Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine

T cells engineered to express HIV-specific chimeric antigen receptors (CARs) represent a promising strategy to clear HIV-infected cells, but to date have not achieved clinical benefits. A likely hurdle is the limited T cell activation and persistence when HIV antigenemia is low, particularly during...

Full description

Bibliographic Details
Main Authors: Blanchard, M.S (Author), Browning, D.L (Author), Burnett, J.C (Author), Cardoso, A.A (Author), Chang, W.-C (Author), Echavarria, L. (Author), Forman, S.J (Author), Guan, M. (Author), Han, T. (Author), Holguin, L. (Author), Le Verche, V. (Author), Li, S. (Author), Lim, L. (Author), Miller, A. (Author), Morris, K.V (Author), Scott, T. (Author), Urak, R. (Author), Vyas, V. (Author), Wang, X. (Author), Yazaki, P. (Author), Zaia, J.A (Author)
Format: Article
Language:English
Published: Cell Press 2022
Subjects:
broadly neutralizing antibody (bNAb)
chimeric antigen receptor T cell (CAR T)
cytomegalovirus (CMV) vaccine
HIV/AIDS
immunotherapy
N6
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items